Nautilus Biotechnology (NAUT) is like:

• Illumina for proteins.

• Nautilus Platform: A proteomics platform designed to quantify and unlock the complexity of the proteome.
• Instruments: Devices that are part of the Nautilus Platform, used for proteomics analysis.
• Consumables: Disposable materials and reagents required for the operation of the Nautilus Platform.
• Software Analysis: Tools and applications within the Nautilus Platform for processing and interpreting proteomics data.

Nautilus Biotechnology, Inc. (NAUT) is a development-stage life sciences company focused on creating and commercializing its Nautilus Platform for proteomics. As a company still in the development and pre-commercialization phase, it has not publicly disclosed specific "major customers" in the traditional sense of large commercial purchasers generating significant revenue.

However, Nautilus Biotechnology's platform is designed to be utilized by other companies and institutions within the broader life sciences, pharmaceutical, and academic research sectors. Therefore, their sales model is primarily business-to-business (B2B), not direct-to-consumer.

Based on the nature of their advanced proteomics technology, the primary categories of customers Nautilus Biotechnology aims to serve upon commercial launch include:

1. Pharmaceutical Companies: For applications in drug discovery, target validation, biomarker identification, and understanding disease mechanisms.
2. Biotechnology Companies: Engaged in various research and development activities across diagnostics, therapeutics, and basic biological understanding.
3. Academic and Government Research Institutions: Universities, medical centers, and national laboratories conducting fundamental and translational research in biology and medicine.

Sujal Patel, Founder & CEO

Sujal Patel is a successful technology entrepreneur who co-founded Nautilus Biotechnology. He previously founded and served as CEO of Isilon Systems, an enterprise data storage company. Isilon Systems completed a successful initial public offering in 2006 and was later acquired by EMC in 2010 for $2.6 billion. After the acquisition, he served as President of EMC's Isilon Storage Division until 2012. He holds a degree in Computer Science and has nineteen patents in storage, networking, and media delivery, as well as five patents related to Nautilus Biotechnology's technology.

Anna Mowry, Chief Financial Officer

Anna Mowry is an experienced finance and business leader who serves as the Chief Financial Officer and Treasurer of Nautilus Biotechnology. Prior to joining Nautilus, she was the VP of Finance and Operations at Igneous. She also held various finance and sales operations leadership roles at Amazon Web Services and Isilon Systems. Anna Mowry holds a BS in Biochemistry and an MBA.

Parag Mallick, PhD, Founder & Chief Scientist

Dr. Parag Mallick is a co-founder of Nautilus Biotechnology and also an Associate Professor at Stanford University. He is an interdisciplinary scientist whose research focuses on computational and experimental systems biology, cancer biology, and nanotechnology, particularly in accelerating the discovery of diagnostic and prognostic protein biomarkers. Dr. Mallick earned his BS in Computer Science and a PhD in Chemistry & Biochemistry, and has over 100 publications and patents in fields including artificial intelligence and proteomics technology.

Matthew Murphy, Esq., General Counsel

Matthew Murphy has served as General Counsel for Nautilus Biotechnology. He has extensive experience in legal operations for high-growth companies in the life sciences sector, having held General Counsel roles at companies such as Pacific Biosciences and 10X Genomics. His expertise includes creating and defending industry-defining patent portfolios.

Ken Suzuki, Chief Marketing Officer

Ken Suzuki was appointed Chief Marketing Officer of Nautilus Biotechnology in September 2024. He brings nearly three decades of experience in the life sciences and technology sector, with a background spanning marketing, product, finance, and research and development. Prior to Nautilus, he spent 25 years at Agilent Technologies, most recently as Vice President and General Manager of its Mass Spectrometry division. He also held roles at Takeda Pharmaceuticals and Hewlett-Packard. He holds an MBA and a BS in Biological Engineering.

The key risks for Nautilus Biotechnology (NAUT) are primarily centered around its status as a development-stage life sciences company pioneering a novel proteomics platform.

1. Development and Commercialization of its Proteomics Platform: Nautilus Biotechnology's entire future is dependent on the successful development, commercialization, and market adoption of its Nautilus proteomics platform. The company's product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict. The company has previously delayed its target for commercializing its technology, now aiming for a product release in late 2026, with primary revenue tied to instrument shipments beginning in 2027. Any delays, inability to launch, or failure to generate market acceptance would significantly impact its prospects. The technology roadmap still involves improving on target binding, reducing off-target binding, and achieving chip stability over hundreds of cycles.
2. Need for Additional Funding and Financial Sustainability: As a development-stage company, Nautilus Biotechnology continues to incur significant operating losses and cumulative deficits. Management anticipates a substantial increase in expenses and capital requirements to continue research and development, scale manufacturing, establish sales, and support commercial launch, indicating an ongoing need to raise additional capital in the future. Although the company has a cash runway projected through 2027, it faces a significant cash burn rate. Furthermore, the company has faced risks of Nasdaq delisting due to non-compliance with the Minimum Bid Price Requirement, which could impact its ability to sell equity securities and reduce stock liquidity. If operating expenses continue to outpace revenue growth post-commercialization, further capital raises could dilute shareholder returns.
3. Intense Competition and Market Adoption of its Technology: The life sciences technology market is highly competitive, featuring larger, established companies with greater name recognition, resources, and extensive intellectual property portfolios. The proteomics ecosystem is already consolidated with major players, challenging smaller companies like Nautilus to differentiate. The success of Nautilus hinges on its platform's ability to effectively solve the "dark matter" problem of the proteome by comprehensively and precisely measuring proteins, which existing tools struggle with. If Nautilus's proprietary Iterative Mapping approach or its Voyager platform's pricing strategy does not gain traction beyond early adopters and key opinion leaders, instrument placements and associated consumables revenue could fall short of expectations.

The successful development and commercialization efforts of Quantum-Si (NASDAQ: QSI), particularly with the launch of its Platinum single-molecule protein sequencing platform in Q3 2023, represents a clear emerging threat to Nautilus Biotechnology. Both companies are developing next-generation, disruptive technologies aimed at comprehensive, high-throughput, single-molecule proteome analysis, seeking to overcome the limitations of current proteomics methods. Quantum-Si's earlier market entry with a functionally analogous platform could capture significant market share and establish an installed base among researchers and drug developers before Nautilus has fully launched its own technology, directly challenging Nautilus's future commercial prospects and competitive positioning in this nascent, high-growth field.

The addressable market for Nautilus Biotechnology's main product, the Nautilus Platform, which is a proteomics platform, is the global proteomics market.

The global proteomics market was estimated at approximately USD 27.8 billion in 2024 and is projected to reach USD 58.16 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.9% from 2025 to 2030. Other estimates place the global proteomics market at around USD 41.5 billion in 2024, with projections to reach USD 139.4 billion by 2033. Additionally, the global proteomics market was valued at USD 41.97 billion in 2025 and is projected to reach USD 125.64 billion by 2034, exhibiting a CAGR of 13.09% during the forecast period.

For the North American region, the proteomics market dominated the global market, accounting for 45.75% of the revenue share in 2024. North America's proteomics market was valued at USD 18.36 billion in 2025. The U.S. proteomics market specifically was valued at USD 13.1 billion in 2025 and is expected to reach USD 42.6 billion by 2034, exhibiting a CAGR of 13.98% during 2026-2034. Another estimate indicates the U.S. proteomics market generated revenue of USD 10,049.4 million in 2023 and is expected to reach USD 21,998.8 million by 2030.

Nautilus Biotechnology itself has indicated that the existing proteomics research market was approximately USD 27 billion annually as of 2022 and is expected to reach approximately USD 55 billion by 2027, representing a CAGR of 15% over the five-year period.

Nautilus Biotechnology (NASDAQ: NAUT) is poised for future revenue growth over the next two to three years, primarily driven by the commercialization and adoption of its Nautilus Platform. Key drivers include the full commercial launch of its Voyager instrument, expansion of its Early Access Program and assay portfolio, and revenue generated from recurring consumables and strategic collaborations.

• Commercial Launch and Instrument Placements: Nautilus plans to initiate the commercial launch of its Voyager platform in late 2026, with instrument installations at customer sites beginning in early 2027. This marks a significant transition from development to a revenue-generating phase for instrument sales. Analysts forecast a significant revenue ramp tied to instruments in 2027.
• Expansion of the Iterative Mapping Early Access Program (EAP): The company launched its Iterative Mapping Early Access Program in January 2026, initially focusing on the Tau proteoform assay. While not expected to be a major revenue driver in 2026, this program is designed to build credibility, momentum, and operational readiness, and modest services revenue is anticipated later in 2026. The EAP will lay the groundwork for broader assay capabilities.
• Broadening Proteoform Assay Portfolio: Nautilus intends to expand its proteoform assay portfolio beyond Tau, with plans to introduce broad-scale capabilities and focus on new targets, such as oncology, into early access later in 2026. This expansion will widen the addressable market for the Voyager platform and increase commercial prospects.
• Recurring Consumables Revenue: As the Nautilus Voyager platform is adopted and instruments are installed, revenue from associated consumables and reagent kits will become a significant recurring stream. This is a common model for life sciences tool companies, with recurring consumables revenue expected to grow following instrument placements.
• Strategic Collaborations and Grant Funding: Ongoing and new strategic collaborations, such as the partnership with The Michael J. Fox Foundation and Weill Cornell Medicine-Qatar for alpha-synuclein proteoform studies, provide grant funding which contributes to the company's revenue. These collaborations also serve to validate the platform and support the development of a diverse assay pipeline.

Share Repurchases

No information is available regarding share repurchases or authorized future share repurchases by Nautilus Biotechnology over the last 3-5 years.

Share Issuance

• In June 2021, Nautilus Biotechnology became a public company through a SPAC merger, resulting in gross proceeds of approximately $345 million. This included $145 million from the SPAC's trust account and a $200 million Private Investment in Public Equity (PIPE) financing.
• In fiscal year 2025, proceeds from the issuance of common stock under an employee stock purchase plan amounted to $156 thousand.
• In fiscal year 2025, proceeds from the exercise of stock options contributed $58 thousand.

Inbound Investments

• The SPAC merger in June 2021 generated approximately $345 million in gross proceeds for the company.
• A $200 million PIPE financing, part of the SPAC merger, was led by investors including Perceptive Advisors, RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., Casdin Capital, and existing Nautilus shareholders.
• In 2025, Nautilus Biotechnology secured $1.2 million in funding from a collaboration with Weill Cornell Medicine Qatar and the Michael J. Fox Foundation for the development of an alpha-synuclein proteoform assay for Parkinson's disease.

Outbound Investments

No information is available regarding outbound investments made by Nautilus Biotechnology over the last 3-5 years.

Capital Expenditures

• Nautilus Biotechnology's purchases of property and equipment, representing capital expenditures, totaled $1.277 million in fiscal year 2025.
• In fiscal year 2024, capital expenditures for purchases of property and equipment amounted to $2.122 million.
• Capital expenditures are primarily focused on advancing the Nautilus Platform, including instruments, consumables, and software analysis, to support platform development and commercial readiness activities. [cite: BACKGROUND, 15, 17]